Taiwan Human Milk Oligosaccharides Market Size & Outlook, 2026-2034
Taiwan Human Milk Oligosaccharides Market Insights
- Based on Deep Market Insights findings, the Taiwan Human Milk Oligosaccharides Market reached USD 2.76 Million in 2025 and is estimated to attain USD 10.6 Million by 2034.
- From 2026 to 2034, the Taiwan market is expected to grow at a steady CAGR of 16.34%.
- Within the Product Type category, 2-Fucosyllactose (2-FL) dominated in 2025 in terms of market size contribution.
- Over the forecast period, Others is forecasted to deliver the fastest growth, positioning it as the most lucrative Product Type segment.
Source: DMI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Taiwan accounted for 0.79% of the global Human Milk Oligosaccharides Market size in 2025.
- By 2034, United States is expected to remain the top global market in terms of size.
- Within Asia Pacific, China is forecasted to dominate the regional Human Milk Oligosaccharides Market size by 2034.
- Korea will be the fastest-growing market in Asia Pacific, projected to achieve USD 14.6 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 2.76 Million |
| Market Size In 2034 | USD 10.6 Million |
| Largest segment | 2-Fucosyllactose (2-FL) |
| Units | Revenue in USD Million |
| CAGR | 16.34% (2026-2034) |
| Segmnetation Covered | |
| Product Type |
|
| Application |
|
| Form |
|
| End user |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Taiwan Human Milk Oligosaccharides Market Product Type 2026-2034 (USD Million)
| Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2-Fucosyllactose (2-FL) | XX.x | XX.x | XX.x | 1.33 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| 3-Fucosyllactose (3-FL) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Lacto-N-neotetraose (LNnT) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Taiwan Human Milk Oligosaccharides Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infant formula | XX.x | XX.x | XX.x | 1.12 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Dietary supplements | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Functional foods and beverages | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Animal nutrition | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Taiwan Human Milk Oligosaccharides Market Form 2026-2034 (USD Million)
| Form | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dry | XX.x | XX.x | XX.x | 1.74 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Liquid | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Taiwan Human Milk Oligosaccharides Market End user 2026-2034 (USD Million)
| End user | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infant nutrition manufacturers | XX.x | XX.x | XX.x | 1.39 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nutraceutical manufacturers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Food and beverage companies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.